Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
RESEARCH TOOLSreports
Holding OTLK?
Track your performance easily
OTLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $12.85
Previous CloseN/A
Volume358.39K
Average Volume (3M)1.22M
Market Cap
$54.54M
Enterprise Value$142.47M
Total Cash (Recent Filing)$3.19M
Total Debt (Recent Filing)$13.41M
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Feb 18, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.51
Shares Outstanding24,905,636
10 Day Avg. Volume1,067,312
30 Day Avg. Volume1,221,529
Standard Deviation0.37
R-Squared0.00570
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.89
Forecast
1Y Price Target
$19.50Price Target Upside774.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Outlook Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market ExclusivityIf LYTENAVA is approved by the FDA, there is an expectation of at least 12 years of market exclusivity and favorable pricing.
Market PotentialOutlook could disrupt over half the ocular anti-VEGF injection market by volume with what could emerge as the first FDA-approved intravitreal formulation of bevacizumab.
Regulatory FlexibilityThe FDA has demonstrated some regulatory flexibility for ONS-5010 since it is believed the agency would appreciate having an approved bevacizumab available rather than compounded product.
Bears Say
Clinical Trial ResultsONS-5010 misses key endpoint of NORSE 8 trial; BLA submission still planned for 1Q25.
Pipeline LimitationsONS-5010 is the company's sole active development program.
Regulatory ChallengesIt's not clear how the FDA is going to recognize the non-inferiority margin at week 12, which was not a pre-specified endpoint and there was no alignment before readout, so the agency will view this as an 'exploratory' endpoint.
---
Ownership Overview
35.90% Insiders
5.11% Mutual Funds
0.08% Other Institutional Investors
52.94% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.87 and its highest was $12.85 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $54.54M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Feb 18, 2025 which is in 31 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Dec 27, 2024. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.803 by -$0.077.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.79.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 24,905,636 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.803. Following the earnings report the stock price went up 18.235%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
---
Outlook Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.50 (774.44% Upside)
$19.50 (774.44% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 722.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.12%
12-Months-Change
Fundamentals
Return on Equity
103.13%
Trailing 12-Months
Asset Growth
-10.77%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.
---
OTLK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in regulatory approvals and clinical trials, along with a strong financial position. However, there were delays in the BLA resubmission timeline and increased expenses. Overall, the positive developments and strategic advancements outweigh the challenges noted.Read More>---
OTLK Stock 12 Month Forecast
Average Price Target
$19.50
▲(774.44% Upside)
Technical Analysis
ESSA Pharma
―
TuHURA Biosciences
―
Citius Pharmaceuticals
―
Kodiak Sciences
―
Eton Pharmaceuticals
―
Fennec Pharmaceuticals
―
Best Analysts Covering OTLK
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-34.67%
reiterated a buy rating 5 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -34.67% per trade.
---